Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Treatment outcomes, antibiotic use and its resistance pattern among neonatal sepsis patients attending Bahawal Victoria Hospital, Pakistan.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: San Francisco, CA : Public Library of Science
    • الموضوع:
    • نبذة مختصرة :
      Background: Sepsis is one of the major causes of neonatal mortality in Pakistan. This study aimed to investigate the treatment outcomes, antibiotic use and its resistance pattern among neonatal sepsis patients attending a tertiary care hospital in Pakistan. We also aimed to identify the factors affecting mortality in neonatal sepsis patients.
      Methods: A descriptive, cross-sectional study was conducted in the pediatric wards of the Bahawal Victoria Hospital, Bahawalpur, Pakistan. All eligible neonatal sepsis patients who were registered at the study site from January 1, 2019 to June 30, 2019 were included in the study. The data collection form included information on patient's characteristics, antibiotic use and its sensitivity pattern, laboratory and microbiological data, and final treatment outcomes. Treatment outcomes included, discharged (with treatment success), leave against medical advice (LAMA), discharged on request (DOR) and death. Multivariable binary logistic regression analysis was used to find the independent factors associated with death. A p-value of less than 0.05 was considered statistically significant.
      Results: Among the total 586 patients, 398 (67.9%) were male, 328 (56%) were preterm, 415 (70.8%) were diagnosed with early onset sepsis, 299 (51%) were born with low birth weight. Most of the patients (n = 484, 82.6%) were treated with amikacin+cefotaxime at the start of treatment. Culture was positive in 52 (8.9%) patients and the most commonly identified bacteria included, Klebsiella species (n = 19, 36.5%) followed by E. coli (n = 15, 28.5%) and Staphylococcus aureus (n = 8, 15.4%). The identified bacterial isolates showed high level of resistance against the antibiotics initiated at the start of the treatment, while resistance against piperacillin+tazobactam, imipenem, vancomycin and linezolid was very low. Just under half of the patients (n = 280, 47.8%) successfully completed the treatment (i.e., discharged with treatment success), while 123 (21%) patients died during treatment. In multivariable binary logistic regression, the factors which still remained significantly associated with neonatal death included, preterm delivery (AOR 9.59; 95% CI 4.41, 20.84), sub-optimal birth weight (AOR 5.13; 95% CI 2.19, 12.04), early onset sepsis (AOR 2.99; 95% CI 1.39, 6.41) and length of hospital stay (AOR 0.76; 95% CI 0.67, 0.88).
      Conclusion: The mortality rate associated with sepsis was high in our study cohort. The bacterial isolates showed high level of resistance against the antibiotics started as the empiric therapy. Rational use of antibiotics can decrease the adverse outcomes in neonatal sepsis patients.
      Competing Interests: The authors have declared that no competing interests exist.
    • References:
      Res Social Adm Pharm. 2020 Jun;16(6):848-849. (PMID: 32201107)
      Paediatr Int Child Health. 2018 Nov;38(sup1):S3-S15. (PMID: 29790842)
      Early Hum Dev. 2012 May;88 Suppl 2:S69-74. (PMID: 22633519)
      Pediatr Infect Dis J. 2009 Jan;28(1 Suppl):S3-9. (PMID: 19106760)
      Lancet Respir Med. 2018 Mar;6(3):223-230. (PMID: 29508706)
      J Pharm Policy Pract. 2016 Sep 22;9:27. (PMID: 27688887)
      Ther Innov Regul Sci. 2020 May;54(3):492-506. (PMID: 33301133)
      Int J Pediatr. 2018 Aug 02;2018:7801272. (PMID: 30174698)
      Drug Des Devel Ther. 2018 Jun 18;12:1759-1767. (PMID: 29950810)
      J Pediatric Infect Dis Soc. 2015 Mar;4(1):11-20. (PMID: 26407352)
      Int J Pediatr. 2016;2016:1897039. (PMID: 28003834)
      Int J Environ Res Public Health. 2019 Mar 15;16(6):. (PMID: 30875876)
      BMJ. 2019 Jan 22;364:k5314. (PMID: 30670451)
      JNMA J Nepal Med Assoc. 2010 Oct-Dec;50(180):277-81. (PMID: 22049890)
      J Pak Med Assoc. 2011 Jul;61(7):625-8. (PMID: 22204232)
      BMC Res Notes. 2018 May 15;11(1):301. (PMID: 29764503)
      Int J Gynaecol Obstet. 2009 Oct;107 Suppl 1:S47-62, S63-4. (PMID: 19815203)
      Lancet Glob Health. 2016 Oct;4(10):e752-60. (PMID: 27633433)
      BMC Res Notes. 2017 Jul 11;10(1):265. (PMID: 28693597)
      Antimicrob Resist Infect Control. 2017 Jun 13;6:63. (PMID: 28630687)
      J Clin Microbiol. 2021 Nov 18;59(12):e0021321. (PMID: 34550809)
      Matern Health Neonatol Perinatol. 2018 Jan 23;4:2. (PMID: 29403648)
      Syst Rev. 2019 Dec 5;8(1):306. (PMID: 31805993)
      Int J Infect Dis. 2013 Nov;17(11):e961-5. (PMID: 23759260)
      J Perinatol. 2013 Jul;33(7):529-32. (PMID: 23328923)
      Infect Drug Resist. 2019 Mar 26;12:687-699. (PMID: 30988635)
      Lancet. 2014 Jul 12;384(9938):189-205. (PMID: 24853593)
      Lancet. 2016 Jan 9;387(10014):168-75. (PMID: 26603918)
      Bull World Health Organ. 2008 Jun;86(6):452-9. (PMID: 18568274)
      Lancet. 2017 Oct 14;390(10104):1770-1780. (PMID: 28434651)
      Int J Health Plann Manage. 2020 Sep;35(5):1041-1054. (PMID: 32700410)
      Lancet. 2005 Mar 26-Apr 1;365(9465):1175-88. (PMID: 15794973)
      BMC Pediatr. 2018 Jun 27;18(1):208. (PMID: 29950162)
      BMC Public Health. 2012 Oct 24;12:904. (PMID: 23095365)
      Clin Microbiol Rev. 2014 Jan;27(1):21-47. (PMID: 24396135)
      Int J Pediatr. 2019 Feb 06;2019:3784529. (PMID: 30881464)
      Scand J Infect Dis. 2006;38(1):36-42. (PMID: 16338836)
      Arch Dis Child. 2013 Feb;98(2):146-54. (PMID: 23142784)
      BMC Infect Dis. 2010 Mar 18;10:72. (PMID: 20298555)
      BMC Infect Dis. 2020 Sep 10;20(1):666. (PMID: 32912140)
    • الرقم المعرف:
      0 (Anti-Bacterial Agents)
    • الموضوع:
      Date Created: 20210113 Date Completed: 20210507 Latest Revision: 20240330
    • الموضوع:
      20240330
    • الرقم المعرف:
      PMC7806133
    • الرقم المعرف:
      10.1371/journal.pone.0244866
    • الرقم المعرف:
      33439876